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SUMMARY
Objective: Epileptic encephalopathy with electrical status epilepticus in sleep (ESES)
is a pediatric epilepsy syndrome with sleep-induced epileptic discharges and acquired
impairment of cognition or behavior. Treatment of ESES is assumed to improve cogni-
tive outcome. The aim of this study is to create an overview of the current evidence for
different treatment regimens in children with ESES syndrome.
Methods: A literature search using PubMed and Embase was performed. Articles were
selected that contain original treatment data of patients with ESES syndrome.
Authors were contacted for additional information. Individual patient data were col-
lected, coded, and analyzed using logistic regression analysis. The three predefined
main outcomemeasures were improvement in cognitive function, electroencephalog-
raphy (EEG) pattern, and any improvement (cognition or EEG).
Results: The literature search yielded 1,766 articles. After applying inclusion and exclu-
sion criteria, 112 articles and 950 treatments in 575 patients could be analyzed.
Antiepileptic drugs (AEDs, n = 495) were associated with improvement (i.e., cognition
or EEG) in 49% of patients, benzodiazepines (n = 171) in 68%, and steroids (n = 166) in
81%. Surgery (n = 62) resulted in improvement in 90% of patients. In a subgroup analy-
sis of patients who were consecutively reported (585 treatments in 282 patients), we
found improvement in a smaller proportion treated with AEDs (34%), benzodiazepines
(59%), and steroids (75%), whereas the improvement percentage after surgery was pre-
served (93%). Possible predictors of improved outcome were treatment category, nor-
mal development before ESES onset, and the absence of structural abnormalities.
Significance: Although most included studies were small and retrospective and their
heterogeneity allowed analysis of only qualitative outcome data, this pooled analysis
suggests superior efficacy of steroids and surgery in encephalopathy with ESES.
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Key Points
• Treatment of ESES syndrome is assumed to improve
cognitive outcome
• This pooled analysis of 575 cases suggests that corti-
costeroids and surgery are most effective, whereas
benzodiazepines may be an appropriate alternative
• Conventional antiepileptic drugs were reported less
effective
• Evidence is limited to mostly retrospective case-series
• A randomized controlled trial is needed to provide def-
inite answers for children with this often devastating
epilepsy syndrome
Electrical status epilepticus in sleep (ESES) was first
described in 1971 in six children with continuous spike-
wave discharges persisting during whole night’s non–rapid
eye movement (NREM) sleep and subsiding on awakening.
In the initial definition, epileptic activity had to be present
during at least 85% of the NREM sleep electroencephalog-
raphy (EEG), recorded on at least three occasions over a
period of at least 1 month. More recently ESES cases
with a spike-wave index of 50–85% were added to the
spectrum.1–4
The clinical presentation of children with an ESES EEG
pattern is variable. The most severe clinical syndrome can
present with global cognitive regression in addition to clini-
cal seizures. However, atypical cases have been described
with developmental delay from birth or developmental
arrest but no regression of cognitive functioning. The age at
onset ranges from 1 to 14 years, with a peak between 4 and
8 years. Although seizures may be absent in up to 20% of
cases, they are most often the presenting symptom, after
which a developmental delay, a developmental arrest, or a
regression in cognitive performance or behavior becomes
evident. The Landau-Kleffner syndrome is closely related
to ESES and is characterized by an acquired aphasia. In
these patients, the cognitive symptoms focus mainly on the
language domain. These clinical syndromes are referred to
as “epileptic encephalopathy with ESES,” ESES syndrome,
or continuous spikes and waves during sleep (CSWS) syn-
drome. The EEG features of ESES frequently resolve spon-
taneously during puberty, whereas cognitive sequelae often
remain.5–7
The concept of ESES was introduced describing patients
with unknown etiology and has been expanded to patients
with structural or genetic abnormalities. Recently, GRIN2A
mutations were found to be present in up to 20%, mostly the
familiar cases.8–10 However, the etiology remains undeter-
mined in the majority of patients.11–13 An underlying
inflammatory process has been suggested, mainly because
steroids appear to be effective in the treatment of ESES syn-
drome. Inflammation may be either the cause of ESES or an
epiphenomenon.4,5,14,15 The mechanism of how continuous
epileptic activity during sleep leads to cognitive decline is
incompletely understood.
Although the importance of (early) treatment of convul-
sive status epilepticus has convincingly been demon-
strated,16 it remains to be established whether treatment of
sleep-induced status epilepticus, the neurophysiologic hall-
mark of ESES syndrome, prevents permanent cognitive
impairment. Treatment decisions are often based on expert
opinion. Mainly small and retrospective studies have
reported on the EEG effects or cognitive outcome of various
conventional antiepileptic drugs, benzodiazepines, steroids,
intravenous immunoglobulins, ketogenic diet, and epilepsy
surgery. So far only one small randomized controlled trial
has been performed that compares levetiracetam with pla-
cebo in patients with ESES.17,18 The aim of this meta-analy-
sis of individual patient data is to create an overview of all
published treatments in children with epileptic
encephalopathy with ESES and their effects on cognitive
outcome or EEG pattern.
Methods
Search strategy
A literature search in PubMed and Embase was per-
formed with various synonyms for ESES and treatment
(Table S1). The initial search was performed in July 2012
yielding 1,663 articles. An update on the May 15, 2013,
resulted in a total of 1,766 articles. The search strategy was
defined by three investigators (VvD, BvdM, and FEJ). The
search was performed by two authors (VvD and BvdM), and
in rare cases of discordant judgment a third author was con-
sulted (FEJ).
Study selection and data acquisition
Published studies were selected for possible inclusion if
the effect of treatment on the EEG pattern or on cognitive
functioning was described. All search results were reviewed
based on title and abstract by applying the inclusion and
exclusion criteria (Fig. 1). Of the selected articles, full texts
were reviewed. A cross-reference check was performed to
prevent missing relevant articles.
The corresponding authors of all selected studies were
contacted for additional individual patient information
including patient characteristics, qualitative and, if possible,
quantitative EEG results, and information on cognitive
functioning. Patients were included in the pooled analysis if
sufficient data were reported in the article or provided by
the author to allow analysis of individual treatment effect
(i.e., if data on EEG or cognition were available before and
after change in one treatment).
Quality assessment/reduction of bias
Case reports and small case series are likely to be
influenced by publication and selection bias. To limit these
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influences, a subgroup analysis was performed includ-
ing only studies reporting all consecutive patients ful-
filling the inclusion criteria in a given specific period.
This approach has been recommended by the Meta-
analysis of Observational Studies in Epidemiology
(MOOSE) study group.19
Figure 1.
Flow chart search and selection process.
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Data extraction and coding of data
A standardized data-extraction form, containing 44 vari-
ables, was created. Patient characteristics before and after
onset of ESES, treatment regimen under analysis (dosage
and duration), and effects on cognitive function and EEG
characteristics were included. Extraction of raw data from
all studies was performed by one author (VvD). A random
selection of 10% of relevant articles was checked by a sec-
ond author (BvdM). There were some small differences in
judgment that were settled by consensus meeting. None of
these differences concerned the primary outcome (cognitive
or EEG improvement).
Primary outcome assessment
The three main outcome measures were improvement in
cognitive function, EEG pattern, and any improvement
(cognition or EEG). To allow a pooled analysis, all available
data were coded according to the following criteria:
Cognition: improvement was defined primarily by the
judgment of the author of the original article or as a gain
of at least 10 IQ points after start of treatment (when both
pre- and post-treatment IQs were available).
EEG: improvement was primarily defined as an
improvement of the sleep-induced status epilepticus pat-
tern, as subjectively indicated by the author, or as a
reduction of at least 25% in Spike Wave Index (SWI, if
pre- and posttreatment spike wave indices were given).
Any improvement: qualitative or quantitative improve-
ment of either cognition, EEG, or both.
Coding of data was performed by two authors: BvdM and
FEJ for seizure type and EEG data. The other variables were
coded by VvD and BvdM. In case of discordant judgment
by the two reviewers the individual patient data were evalu-
ated by a third independent reviewer (VvD or FEJ).
Statistical analysis
The baseline characteristics and effect of individual treat-
ments were analyzed using IBM SPSS Statistics Software
version 20. The baseline characteristics of the patients from
consecutive cohorts were compared to those of the total
study population, using the chi-square test for categorical
variables (with Yates’ Correction for Continuity for bino-
mial variables) and the Mann-Whitney U-test for continu-
ous variables (as these variables were not normally
distributed). The same tests were applied to compare
patients with known etiology to those with unknown etiol-
ogy. The proportion of patients that showed improvement
after the analyzed treatment is reported for all patients and
for the subgroup of consecutive patients. The corresponding
95% confidence intervals were calculated using normal
approximation methods.
To identify variables that influence treatment outcome, a
predictor analysis was performed with univariate and multi-
variate logistic regression analysis. Univariate analysis was
performed for treatment category, gender, age at diagnosis,
interval from diagnosis to treatment under evaluation, his-
tory of febrile seizures, mental development before the
onset of ESES, presence of computed tomography (CT) or
magnetic resonance imaging (MRI) abnormalities and for
the number of previous treatments. This analysis was first
performed including only “complete cases” regarding
included determinants, that is, cases for which complete
predictor data were available. To account for missing data, a
sensitivity analysis using multiple imputation methods was
then performed, a procedure recommended for datasets with
a significant proportion of missing data.20 All analyzed pos-
sible predictors with missing data were included in the
model to allow an analysis of all treatments. Ten imputed
datasets were created and a pooled analysis was carried out.
The same procedure was used to perform a multivariate
logistic regression analysis including treatment category
and other possible predictors. There was a substantial
proportion of missing data for most possible predictors.
Therefore, a multivariate analysis including only complete
cases for all predictors would result in an analysis of only a
small number of patients and is not reported.
Results
Study and patient selection
The search strategy and study and patient selection are
shown in Figure 1. Descriptive information of the 112
included studies is available in Table S2. The included arti-
cles were published between 1977 and 2013. Some of these
112 articles showed overlap in patient population and were
therefore included as 98 patient cohorts (grouping patients
from the same center and integrating data of duplicate
cases). From 94 (96%) of these 98 cohorts, cognitive out-
come was reported, and from 88 (90%) EEG outcome. The
treatment categories that were analyzed were conventional
antiepileptic drugs in 48 cohorts, benzodiazepines in 23
cohorts, steroids in 41 cohorts, surgery in 18 cohorts, and
other treatments in 11 cohorts. The consecutive subgroup
consisted of patients reported in 23 articles, which could be
included as 15 different patient cohorts. The number of
patients per included cohort was substantially higher in the
consecutive subgroup (mean 23, median 10) compared to
the total included population (mean 6, median 2).
Additional individual patient data were provided by 29
authors for 413 patients, of whom 675 individual treatments
could be included in this analysis. By combining the data of
112 original articles with additional information provided
by the authors, data of 575 patients could be included in
whom 950 individual treatments and their effect were
reported. The subgroup of consecutive patients consisted of
282 patients with 585 individual treatments.
Patient characteristics
A large majority (94%) of patients had at least one sei-
zure, and their first seizure occurred at a median age of three
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and a half years, two and a half years prior to ESES diagno-
sis. Seizures were focal in 45% and generalized in 21%, and
in 28% of patients both focal and generalized seizures were
reported. Abnormal development was already present
before ESES onset in 46% of patients. In 46% of all
included patients, structural abnormalities were seen on CT
or MRI, whereas a genetic or metabolic abnormality was
reported in only a small proportion of patients (7% and 1%,
respectively). The available baseline characteristics of all
patients, and of those reported consecutively, are displayed
separately in Table 1. Except for a different distribution in
seizure types, no significant differences between both
groups were detected. A comparison between patients with
known etiology and those with unknown etiology revealed a
larger proportion with an abnormal perinatal history, abnor-
mal development before ESES onset, and CT/MRI abnor-
malities in patients with known etiology. These patients
also had more frequent seizures, and a smaller proportion of
them had a positive family history for epilepsy (Table S3).
Treatment response
The overall treatment effect (“any improvement”) is
reported including 95% confidence intervals in Table 2.
Any improvement was seen in 49% of patients treated with
conventional antiepileptic drugs (AEDs) and in 68% of
patients treated with benzodiazepines. Treatment with ster-
oids was associated with any improvement in 81% of
patients, surgery in 90%, and other treatments in 54% of
patients. Surgical techniques applied in 62 patients included
multiple subpial transection (n = 31), hemispheric surgery
(n = 13), corpus callosotomy (n = 9), lobar resection
(n = 5), multilobar resection or disconnection (n = 2) and
in two patients underwent other surgical procedures
(cystoperitoneal shunting and an unspecified procedure).
Cognitive improvement was seen after treatment with AEDs
in 40%, benzodiazepines in 50%, steroids in 78%, and after
surgery in 80%. EEG improvement was seen after treatment
with AED in 45%, benzodiazepines in 59%, steroids in
70%, and after surgery in 80% of the patients (Table 2).
Of 771 included treatments (81% of all included treat-
ments), outcome data were separately reported for cognition
and EEG (for the remainder only data on “any improve-
ment” were available). In these cases any improvement was
seen after 470 treatments (61%). Of the 470 treatments that
were associated with any improvement, 77 treatments
(16%) were associated with EEG improvement without
Table 1. Patient characteristics
All patientsa “Consecutive patients”a,b p-Value for comparisonc
Number of patients 575 282
Male 333/550 (61%) 166/282 (59%) 0.69
Abnormal perinatal history 138/341 (40%) 118/256 (46%) 0.20
Positive family history for epilepsy 49/238 (21%) 41/196 (21%) 1.00
History of febrile seizures 32/497 (6%) 22/204 (11%) 0.07
Mean/median age at seizure onset 44/42 months (n = 384) 42/36 months (n = 212) 0.16
Mean/median age at developmental delay, arrest or regression 65/60 months (n = 306) 68/63 months (n = 205) 0.24
Mean/median age at ESES diagnosis 75/72 months (n = 416) 77/78 months (n = 240) 0.20
CT/MRI abnormalities 213/461 (46%) 147/273 (54%) 0.05
Presumed etiology
Genetic 29/432 (7%) 26/266 (10%) 0.28
Structural 215/432 (50%) 136/266 (51%)
Metabolic 2/432 (1%) 0/266 (0%)
Unknown 186/432 (43%) 104/266 (39%)
Abnormal development prior to ESES onset 167/362 (46%) 141/261 (54%) 0.06
Type of (previous) seizures
None 26/464 (6%) 7/261 (3%) 0.00
Focal 208/464 (45%) 93/261 (36%)
Generalized 98/464 (21%) 43/261 (17%)
Both 132/464 (28%) 118/261 (45%)
Frequency of seizures at inclusion
None 43/261 (17%) 20/209 (10%) 0.16
Monthly 97/261 (37%) 88/209 (42%)
Weekly 37/261 (14%) 34/209 (16%)
Daily 84/261 (32%) 67/209 (32%)
Mean/median follow up duration after start of treatment 36/24 months (n = 349) 36/24 months (n = 172) 0.15
Number of treatments 950 585
aPatient characteristics are shown as number of patients with this characteristic/total number of patients for whom this characteristic is available and the corre-
sponding percentage.
b“Consecutive patients” = patients included from studies reporting all consecutive patients fulfilling the inclusion and exclusion criteria in a specified period.
cp-Values are reported for the comparison of baseline characteristics of the patients from consecutive cohorts to those of the total study population. The two
groups were compared using the chi-square test for categorical variables (with Yates’ correction for continuity for binomial variables) and the Mann-Whitney
U-test for continuous variables.
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cognitive improvement and 69 treatments (15%) were asso-
ciated with cognitive improvement without EEG improve-
ment. After 324 treatments (69%), both cognitive
performance and EEG were reported to have improved. A
subgroup analysis was performed on the 282 patients who
were treated consecutively in reporting centers, with 585
individual treatments. In this subgroup improvement per-
centages were lower for AEDs (34%), benzodiazepines
(59%), and steroids (75%). The percentage of patients who
improved after surgery was similar in this subgroup (93%).
Predictors of treatment response
Subsequently, we analyzed possible predictors of treat-
ment effect, including treatment category and patient
characteristics (Table 3). “Any improvement” was associ-
ated with benzodiazepines, steroids, and surgery when
compared to treatment with AEDs. An abnormal devel-
opment of patients prior to ESES onset was associated
with no improvement after treatment. The presence of
CT/MRI abnormalities in nonsurgically treated patients
and a lower number of previous treatments were signifi-
cant predictors of poor treatment response in univariate
analysis. However, this correlation did not sustain in
multivariate analysis. These variables showed substantial
differences among the treatment categories (Table S4).
Male gender predicted better treatment response only in
multivariate analysis of pooled data after multiple impu-
tation. Separate analyses of possible predictors of EEG
Table 2. Reported treatment effect (percentage improved) in patients with encephalopathy with ESES
All/consecutive subgroup Any improvement, % (95% CI) Cognitive improvement, %a (95% CI) EEG improvement, %b (95% CI)
AED All (n = 495) 49 (44–53) 40 (23–31) 45 (41–50)
Cons. (n = 310) 34 (29–39) 32 (26–37) 33 (28–38)
Benzodiazepines All (n = 171) 68 (61–75) 50 (42–59) 59 (52–67)
Cons. (n = 107) 59 (50–68) 45 (35–54) 46 (37–56)
Steroids All (n = 166) 81 (75–87) 78 (72–85) 70 (62–77)
Cons. (n = 100) 75 (67–83) 70 (60–79) 68 (58–77)
Surgery All (n = 62) 90 (83–98) 80 (70–90) 80 (68–91)
Cons. (n = 30) 93c 83 (70–97) 74 (58–91)
Other All (n = 56) 54 (41–67) 67 (51–82) 29 (15–43)
Cons. (n = 38) 58 (42–74) 71 (53–89) 26 (8–44)
Total All (n = 950) 61 (58–64) 53 (49–56) 54 (50–56)
Cons. (n = 585) 50 (46–54) 44 (40–49) 43 (39–47)
N, number of treatments analyzed; any improvement, improvement of cognition or EEG; missing n, missing number of treatments for this outcome; 95% CI,
95% confidence interval; AED, conventional antiepileptic drugs.
aFor 126 (all patients)/40 (consecutive subgroup) treatments cognitive outcome was missing.
bFor 68 (all patients)/25 (consecutive subgroup) treatments EEG outcome was missing.
cNo 95% confidence interval mentioned due to small sample size and large proportion.
Table 3. Odds of treatment response (any improvement)
Treatment
OR (95% CI)
Univariate (complete case)
OR (95%CI)
Univariate (MI)
OR (95% CI)
Multivariate (MI)
AED Reference Reference Reference
Benzodiazepines 2.2 (1.5–3.2)* 2.2 (2.0–2.5)* 2.1 (1.4–3.1)*
Steroids 4.4 (2.9–6.7)* 4.4 (3.9–5.0)* 4.2 (2.7–6.5)*
Surgery 9.8 (4.1–23.1)* 9.8 (7.5–12.6)* 8.6 (3.5–21.4)*
Other 1.2 (0.69–2.1) 1.2 (1.0–1.4)* 1.1 (0.6–2.0)
Patient characteristics
Male gender 1.2 (0.9–1.6) 1.2 (0.9–1.5) 1.4 (1.0–1.8)*
Age at diagnosis 1.0 (1.0–1.0) 1.0 (1.0–1.0) 1.0 (1.0–1.0)
Interval diagnosis—treatment 1.0 (1.0–1.0) 1.0 (1.0–1.0) 1.0 (1.0–1.0)
Febrile seizures 1.2 (0.7–2.1) 1.3 (0.7–2.3) 1.4 (0.8–2.6)
Abnormal development before ESES onset 0.6 (0.5–0.9)* 0.6 (0.5–0.8)* 0.6 (0.4–0.8)*
CT/MRI abnormalities 0.8 (0.6–1.1) 0.8 (0.6–1.1) 1.0 (0.7–1.4)
CT/MRI abnormalities in nonsurgically treated patients 0.7 (0.5–1.0)* 0.7 (0.5–1.0) 1.0 (0.7–1.4)
Number of previous treatments 1.2 (1.1–1.4)* 1.1 (0.9–1.3) 1.1 (0.9–1.0)
OR, odds ratio; AED, conventional antiepileptic drugs; complete case, complete case analysis; 95% CI, 95% confidence interval; MI, pooled analysis after using
multiple imputation methods. Confidence intervals are indicated by italic type.
Multivariate analysis was performed using patient characteristics and treatment category as covariates.
*p < 0.05.
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and cognitive outcome provided comparable results
(Table S5).
Discussion
The results of this individual patient data meta-analysis
suggest that treatment with steroids and surgery (in suitable
candidates) are most effective in the treatment of ESES syn-
drome. Treatment success percentages (for EEG or cogni-
tive improvement) were reported between 80% and 90% for
steroids and surgery, and these results are relatively pre-
served in the consecutive subgroup analysis. Benzodi-
azepines may be considered an appropriate alternative, with
69% and 59% overall treatment success in all and consecu-
tive patients, respectively. Conventional AEDs were
reported less effective in the included studies, with improve-
ment seen in 49% and 34% of all patients and consecutive
patients, respectively. Improvement most frequently
reflected both EEG and cognitive outcomes. The strong
influence of the treatment category chosen on treatment
effect persists in a multivariate analysis with possible pre-
dictors. Among patient characteristics, developmental level
before the onset of ESES was the only predictor with sus-
tained significance in all analyses.
Normal development before the onset of ESES was found
to be a significant predictor of treatment success, and this
association was significant in all analyses. This confirms
earlier observations that IQ, presence of cognitive impair-
ment, and duration of cognitive impairment before the start
of a treatment predict treatment response in patients with
ESES.13,21,22 However, in many patients it is unclear if
“preexistent” abnormal development was unrelated to, or a
first sign of “late recognized” ESES. Diagnostic delay is an
important issue in children with epilepsy (especially in syn-
dromes with nonconvulsive seizures or status epilepticus)
and is associated with more severe cognitive impairment.23
In our multivariate analysis the number of previous treat-
ments was not associated with treatment efficacy. This con-
trasts to the results of a large study of AEDs for epilepsy in
general, where a strong decrease in efficacy is seen after
failure of a previous AED.24 A possible explanation is that
our approach focuses on cognition and EEG abnormalities
and not on seizure freedom. Some treatments may have
been prescribed primarily to control seizures, although they
were reported in the context of an ESES diagnosis. In gen-
eral, we hypothesize that there is a tendency to initially pre-
scribe a conventional AED (especially in patients
presenting with frequent seizures) or benzodiazepine and to
consider corticosteroids and surgery (often more successful)
only in refractory cases. This hypothesis is supported by the
observation that the mean number of previous treatments is
higher for treatment with steroids and surgery than with
AEDs in our dataset (Table S4). These differences could
potentially result in higher success rates for the drugs
prescribed later in the course of ESES syndrome. Overall,
better outcomes have been reported in cases with unknown
etiology, as compared to cases with structural lesions,
except for surgically treated patients.11,13 We found that a
structural lesion predicts unsuccessful treatment in univari-
ate analysis for nonsurgical treatments. However, this asso-
ciation could not be confirmed in multivariate analysis.
The results have to be interpreted in the setting of data
acquisition. Many of the included studies are small and ret-
rospective. These case reports and small case series may
have been published because of an exceptionally good or
bad treatment effect, causing selection and publication bias.
This is consistent with the observed differences in treatment
effect among all patients and in the subgroup of consecutive
patients. The only randomized controlled trial compared
levetiracetam treatment with placebo and found a signifi-
cant reduction in spike-wave activity. No significant influ-
ence on cognitive performance was observed. The broad
inclusion criteria of this trial (SWI >30%, many patients
with only behavioral disturbances) and small sample size
(n = 18 after exclusion of dropouts) limit the clinical rele-
vance of these findings. This study could not be included in
this meta-analysis as insufficient individual patient data
were available.17,18 In addition, the large heterogeneity of
the included studies allowed analysis of qualitative outcome
data only. Most authors clearly reported whether cognitive
or EEG improvement was seen after treatment. We pre-
ferred to use quantitative data; however, this was not possi-
ble due to missing quantitative data for a majority of
patients. Furthermore, due to the limited size of the included
studies it was not possible to account for heterogeneity
between studies in the analysis. The analysis was limited to
a fixed-effect analysis of the individual patient data, and
data were treated as a single study dataset. Moreover, speci-
fic treatments that may differ in efficacy had to be clustered
in our analysis, because the quality and quantity of data
were insufficient for valid treatment-specific analysis. Fur-
thermore, adverse effects and relapse rates are not included
in the analysis because of missing data. Finally, we could
not include treatment duration and dosage in the analysis as
these were not reported in the majority of studies. Because
follow-up periods are heterogeneous in different studies, we
were not able to evaluate outcomes at comparable points in
time. This point is particularly relevant in a disorder where
natural fluctuations in severity occur over time. In this con-
text, a positive or negative effect may be incorrectly attribu-
ted to a drug effect when it may have represented just a
natural fluctuation in the course of the disease. Only
prospective controlled trials with long follow-up will be
able to distinguish natural fluctuations in the disease from
treatment effects.
The effect of treatment on seizure frequency was not
included in this study, as we believe that cognitive distur-
bances and EEG abnormalities are the hallmarks of the
syndrome and we considered these the most important
outcomes of specific treatment for ESES syndrome.
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Despite these challenges, this study provides valuable
information. To our knowledge, it is the first pooled analy-
sis of individual patient data evaluating the effect of differ-
ent treatment regimens in patients with epileptic
encephalopathy with ESES. The individual patient data
meta-analysis approach allowed us to investigate the effect
of a large number of individual treatments by combining
the information from original articles with additional data
provided by many authors. The adoption of an individual
patient data analysis design has several advantages as com-
pared to an aggregate analysis of literature reports only.
Consistent inclusion and exclusion criteria can be used
across studies and individual patients. In addition, missing
data of individual patients can be observed and accounted
for in the analysis at the individual level. Furthermore,
studies that contain overlapping sets of patients can be
identified and excluded from analyses, and the use of indi-
vidual patient data enhances the possibilities of statistical
testing.25 We performed a subgroup analysis of consecu-
tive patients, reducing the effects of publication bias. In
addition, a predictor analysis was reported. By using multi-
variate logistic regression analysis we limited the influence
of many possible confounders.
Our data suggest that surgery may be the most effective
treatment for children with ESES syndrome. However,
many of these surgically treated patients had a structural
lesion and it is unlikely that surgery is equally effective in
patients with ESES syndrome of unknown etiology, and it is
unclear which technique can be applied in these patients.
Multiple subpial transection (MST) has been suggested as a
treatment option in Landau-Kleffner syndrome, but evi-
dence is limited and it is unclear whether MST can also be
beneficial in ESES patients with cognitive deficits outside
the language domain.26 Furthermore, adverse effects were
not included in this analysis and reported qualitative
improvement may not be sufficient to justify the risk of sur-
gery. However, it is likely that surgery is underutilized and
that surgery should be considered sooner in the treatment of
ESES patients with regression of cognitive functioning and
a structural lesion that is accessible for resection or discon-
nection.
In summary, this study provides new insights by combin-
ing the available evidence from mostly small and retrospec-
tive studies. Despite the large number of patients and
treatments evaluated in the pooled analysis, no definite con-
clusions can be drawn on treatment effects. A very recent
study showed that clinicians’ approaches to the treatment of
ESES syndrome differ a lot and although the current study
is a step forward, no general recommendations can be
made.27 Further research is urgently needed to provide defi-
nite answers regarding treatment of children with this, often
devastating, epilepsy syndrome. A randomized controlled
European multicenter trial was recently initiated and may
provide further directions (RESCUE ESES, Randomized
European trial of Steroids versus Clobazam Usage for
Encephalopathy with Electrical Status Epilepticus in
Sleep).
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